Dependence Risk
Study register · detail Narrative Review (Nature Reviews) · Dependence Risk · 2021

Cannabis use and cannabis use disorder

Mixed 495 citations
SampleNarrative Review
Blindingunklar
DesignNarrative Review (Nature Reviews)
Key finding

Psychosocial interventions effectively reduce cannabis use, lasting abstinence remains rare; no approved pharmacotherapy available.

Summary

Narrative review (Nature Reviews) on cannabis use disorder (CUD): ~10% of the 193 million cannabis users worldwide develop CUD; psychosocial therapies (CBT, MET, contingency management) significantly reduce use; no approved pharmacotherapies; legalization may increase CUD prevalence through availability of stronger products.

SummaryNarrative review on cannabis use disorder (CUD): About 10% of the 193 million cannabis users worldwide develop a CUD; psychosocial therapies (CBT, MET, contingency management) effectively reduce use, but without frequent lasting abstinence; approved pharmacotherapies are still lacking.
Quality profile
Sample size
Blinding
Effect size Mixed
Citations / year
Authors
Connor J P, Stjepanović D, Le Foll B et al.
DOI 10.1038/s41572-021-00247-4
Design: Narrative Review (Nature Reviews)
Share
Abstract
Cannabis use disorder (CUD) is an underappreciated risk of using cannabis that affects ~10% of the 193 million cannabis users worldwide. The individual and public health burdens are less than those of other forms of drug use, but CUD accounts for a substantial proportion of persons seeking treatment for drug use disorders owing to the high global prevalence of cannabis use. Cognitive behavioural therapy, motivational enhancement therapy and contingency management can substantially reduce cannabis use and cannabis-related problems, but enduring abstinence is not a common outcome. No pharmacotherapies have been approved for cannabis use or CUD, although a number of drug classes (such as cannabinoid agonists) have shown promise and require more rigorous evaluation. Treatment of cannabis use and CUD is often complicated by comorbid mental health and other substance use disorders. The legalization of non-medical cannabis use in some high-income countries may increase the prevalence of CUD by making more potent cannabis products more readily available at a lower price. States that legalize medical and non-medical cannabis use should inform users about the risks of CUD and provide information on how to obtain assistance if they develop cannabis-related mental and/or physical health problems.

The impediment to action advances action. — Marcus Aurelius